Population pharmacokinetic of antiepileptic drugs in different populations

• Authors: Jasmina Milovanovic , Slobodan Jankovic
• Languages of publication: EN

Abstracts

EN

This article reviews a population pharmacokinetics studies conducted during the past few years in Serbia. Studies have included three the most frequently used antiepileptic drugs (valproate, carbamazepine and lamotrigine) and different populations of epileptic patients: children, adults and heterogeneous population composed of both children and adults. The review compares obtained values of population pharmacokinetic models of clearance of these drugs, and factors that are significantly determined, making brief comments on the results of other authors on the same topic. Individualization of drug dosage is the basis of rational therapy, and factors of variability will always be subject of scientific research.

Keywords

EN

Population pharmacokinetics; ENONMEM; Valproate; Carbamazepine; Lamotrigine

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 4
• Pages: 383-391

Dates

published

1 - 8 - 2013

online

12 - 6 - 2013

Contributors

author

Jasmina Milovanovic

• Pharmacology Department, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

author

Slobodan Jankovic

• Pharmacology Department, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

References

• [1] Williams P.J., Ette E.I., The role of population pharmacokinetics in drug development in light of the Food and Drug Administration’s ‘Guidance for Industry: Population Pharmacokinetics’, Clin. Pharmacokinet., 2000, 39, 385–395 http://dx.doi.org/10.2165/00003088-200039060-00001[Crossref]
• [2] Milovanovic J.R., Jankovic S.M., Population pharmacokinetics, Vojnosanit. Pregl., 2005, 11, 847–850 (in Serbian) http://dx.doi.org/10.2298/VSP0511847M[Crossref]
• [3] Beal S.L., Sheiner L.B., NONMEM Users Guides. NONMEM Project Group, University of San Francisko, San Francisko, CA, 1998
• [4] Aarons L., Software for population pharmacokinetics and pharmacodinamics, Clin. Pharmacokinet., 1999, 36, 255–264 http://dx.doi.org/10.2165/00003088-199936040-00001[Crossref]
• [5] Milovanović J.R., Antiepileptic drugs and population pharmacokinetics, Foundation Andrejevic, Belgrade, Serbia, 2009 (in Serbian)
• [6] Jankovic S.M., Milovanovic J.R., Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients, Methods. Find. Exp. Clin. Pharmacol., 2007, 29, 673–679 http://dx.doi.org/10.1358/mf.2007.29.10.1116313[Crossref]
• [7] Jankovic S.M., Jovanovic D., Milovanovic J.R., Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients, Methods. Find. Exp. Clin. Pharmacol., 2008, 30, 707–13 http://dx.doi.org/10.1358/mf.2008.30.9.1323496[Crossref]
• [8] Jankovic S.M., Milovanovic J.R., Jankovic S., Factors influencing valproate pharmacokinetics in children and adults, Int. J. Clin. Pharmacol. Ther., 2010, 48, 767–775 [Crossref]
• [9] Milovanovic J.R., Jankovic S.M., Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis, Int. J. Clin. Pharmacol. Ther., 2011, 49, 428–436 [Crossref]
• [10] Milovanovic J.R., Jankovic S.M., Population pharmacokinetics of lamotrigine in patients with epilepsy, Int. J. Clin. Pharmacol. Ther., 2009, 47, 752–760 [Crossref]
• [11] Yukawa E., Population-based investigations of drug relative clearance using nonlinear mixedeffect modelling from information generated during the routine clinical care of patients, J. Clin. Pharm. Ther., 1999, 24, 103–113 http://dx.doi.org/10.1046/j.1365-2710.1999.00204.x[Crossref]
• [12] Sheiner L.B., Beal S.L., Some suggestions for measuring predictive performance, J. Pharmacokinet. Biopharm., 1981, 9, 503–512 http://dx.doi.org/10.1007/BF01060893[Crossref]
• [13] Bondareva I.B., Jelliffe R.W., Sokolov A.V., Tishenkova I.F., Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage, J. Clin. Pharm. Ther. 2004, 29, 105–120 http://dx.doi.org/10.1111/j.1365-2710.2003.00538.x[Crossref]
• [14] Peterson G.M., Naunton M., Valproate: a simple chemical with so much to offer, J. Clin. Pharm. Ther., 2005, 30, 417–421 http://dx.doi.org/10.1111/j.1365-2710.2005.00671.x[Crossref]
• [15] Yukawa E., To H., Ohdo S., Higuchi S., Aoyama T., Population-based investigation of valproic acid relative clearence using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics, J. Clin. Pharmacol., 1997, 37, 1160–1167 http://dx.doi.org/10.1002/j.1552-4604.1997.tb04301.x[Crossref]
• [16] Botha J.H., Gray A.L., Miller R., A model for estimating individualized valproate clearance values in children, J. Clin. Pharmacol., 1995, 35, 1020–1024 http://dx.doi.org/10.1002/j.1552-4604.1995.tb04020.x[Crossref]
• [17] EL Desoky E.S., Faseau E., Amry E.L. Din, Cosson V., Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian patients, Eur. J. Clin. Pharmacol., 2004, 59, 783–790 http://dx.doi.org/10.1007/s00228-003-0699-7[Crossref]
• [18] Blanco Serrano B., Garcia Sanchez M.J., Otero M.J., Santos Buelga D., Serrano J., Dominguez-Gil A., Valproate population pharmacokinetics in children, J. Clin. Pharm. Ther., 1999, 24, 73–80 http://dx.doi.org/10.1046/j.1365-2710.1999.00202.x[Crossref]
• [19] Blanco Serrano B., Otero M.J., Santos Buelga D., Garcia Sanchez M.J., Serrano J., Dominguez-Gil A., Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data, Biopharm. Drug. Dispos., 1999, 20, 233–240 http://dx.doi.org/10.1002/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5[Crossref]
• [20] Park H.M., Kang S.S., Lee Y.B., Shin D.J., Kim O.N., Lee S.B., Yim D.S., Population pharmacokinetics of intravenous valproic acid in Korean patients, J. Clin. Pharm. Ther., 2002, 27, 419–425 http://dx.doi.org/10.1046/j.1365-2710.2002.00440.x[Crossref]
• [21] Correa T., Rodriquez I., Romano S., Population pharmacokinetics of Valproate in Mexican Children with epilepsy, Biopharm. Drug. Dispos., 2008, 29, 511–520 http://dx.doi.org/10.1002/bdd.636[Crossref]
• [22] Garcia M.J., Santos Bulega D., Otero M.J., Serrano J., Blanco B, Dominquez-Gil A., Population Pharmacokinetics: Effect of Politherapy on Valproic acid clearance, 1997, June 23–24, Glasgow, Scotland, http://www.page-meeting.org/?abstract=657
• [23] Yukawa E., To H., Ohdo S., Higuchi S., Aoyama T., Detection of carbamazepine induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening, J. Pharm. Pharmacol., 1997, 49, 751–756 http://dx.doi.org/10.1111/j.2042-7158.1997.tb06106.x[Crossref]
• [24] Jiao Z., Zhong M.K., Shi X.J., Hu M., Zhang J., Population pharmacokinetics of carbamazepine in Chinese epilepsy patients, Ther. Drug. Monit., 2003, 25, 279–286 http://dx.doi.org/10.1097/00007691-200306000-00005[Crossref]
• [25] Katzung B.G., Basic and clinical pharmacology, McGraw-Hill, Boston, 2007
• [26] Sweetman S.C., Martindale: The complete drug reference 36, Pharmaceutical Press, London, UK, 2009
• [27] Delgado Iribanegaray M.F., Santos Buelga D., Garcia Sanchez M.J., Otero M.J., Falcao A.C., Dominguez-Gil A., Carbamazepine population pharmacokinetics in children: mixed-effect models, Ther. Drug. Monit., 1997, 19, 132–139 http://dx.doi.org/10.1097/00007691-199704000-00003[Crossref]
• [28] Baciewicz A.M., Carbamazepine drug interaction, Ther. Drug. Monit., 1986, 8, 305–317 http://dx.doi.org/10.1097/00007691-198609000-00012[Crossref]
• [29] Jiao Z., Shi X.J., Zhao Z.G., Zhong M.K., Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data, J. Clin. Pharm. Ther., 2004, 29, 247–256 http://dx.doi.org/10.1111/j.1365-2710.2004.00557.x[Crossref]
• [30] Yukawa E., Aoyama T., Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data, J. Clin. Pharmacol., 1996, 36, 752–759 http://dx.doi.org/10.1002/j.1552-4604.1996.tb04246.x[Crossref]
• [31] Gray A.L., Botha J.H., Miller R., A model for determination of carbamazepine clearance in children on mono- and polytherapy, Eur. J. Clin. Pharmacol., 1998, 54, 359–362 http://dx.doi.org/10.1007/s002280050475[Crossref]
• [32] Anderson G.D., Children versus adults: pharmacokinetics and averse-effects differences, Epilepsia, 2002, 43, 53–59 http://dx.doi.org/10.1046/j.1528-1157.43.s.3.5.x[Crossref]
• [33] Chan E., Lee H.S., Hue S.S., Population pharmacokinetics of carbamazepine in Singapore epileptic patients, Br. J. Clin. Pharmacol., 2001, 51, 567–576 http://dx.doi.org/10.1046/j.0306-5251.2001.01396.x[Crossref]
• [34] Reith D.M., Hooper W.D., Parke J., Charles B., Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents and adults, J. Pharmacokinet. Pharmacodynam., 2001, 28, 79–92 http://dx.doi.org/10.1023/A:1011569703060[Crossref]
• [35] Ahn J.E., Birnbaum A.K., Brundage R.C., Inherent correlation between dose and clearance iin therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses, J. Pharmacokinet. Pharmacodyn., 2005, 32, 703–718 http://dx.doi.org/10.1007/s10928-005-0083-6[Crossref]
• [36] Kumps A.H., Dose-dependency of the ratio between carbamazepine serum levels and dosage in patients with epilepsy, Ther. Drug. Monit., 1981, 3, 271–274 http://dx.doi.org/10.1097/00007691-198103000-00007[Crossref]
• [37] Martin E.S., Crismon M.L., Godley P.J., Postinduction carbamazepine clearance in an adult psychiatric population, Pharmacotherapy, 1991, 11, 296–302
• [38] Chung A.M., Eiland L.S., Use of second-generation antiepileptic drugs in the pediatric population, Paediatr. Drugs, 2008, 10, 217–545 http://dx.doi.org/10.2165/00148581-200810040-00003[Crossref]
• [39] Valencia I., Pinol-Ripoll G., Khurana D.S., Hardison H.H., Kothare S.V., Melvin J.J., et al., Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy, Eur. J. Paediatr. Neurol., 2009, 13, 141–145 http://dx.doi.org/10.1016/j.ejpn.2008.03.002[Crossref]
• [40] Johannessen S.I., Tomson T., Pharmacokinetic variability of newer antiepileptic drugs, Clin. Pharmacokinet., 2006, 45, 1061–1075 http://dx.doi.org/10.2165/00003088-200645110-00002[Crossref]
• [41] Chen C., Grasela T.H., Phillips L., Friedler-Kelly J.B., Womble G., Risner M.E., Yau M.K., Population pharmacokinetics of add-on lamotrigine in pediatric patients, Ann. Neurol., 1997, 42, 508
• [42] Chen C., Validation of a population pharmacokinetical model for adjunctive lamotrigine therapy in children, J. Clin. Pharmacol., 2000, 50, 135–145 [Crossref]
• [43] Gidal B.E., Anderson G.D., Rutecki P.R., Shaw R., Lanning A., Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy, Epilepsy Res., 2000, 42, 23–31 http://dx.doi.org/10.1016/S0920-1211(00)00160-1[Crossref]
• [44] Rivas N., Buelga D.S., Santos-Borbujo J., Otero M.J., Dominguez-Gill A., Garcia M.J., Population pharmacokinetics of lamotrigine in epileptic patients with data proceeding of therapeutic drug monitoring, Annual Meeting of the Population Approach Group in Europe, 2005, June 16–17, Pamplona, Spain, http://www.page-meeting.org/?abstract=732
• [45] Rivas N., Buelga D.S., Elger C.E., Santos-Borbujo J., Otero M.J., Dominguez-Gill A., Garcia M.J., Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy, Ther. Drug. Monit., 2008, 30, 483–489
• [46] Punyawudho B., Ramsay E.R., Macias F.M., Rowan J.A., Collins J.F., Brundage R.C., et al., Population pharmacokinetics of lamotrigine in elderly patients, J. Clin. Pharmacol., 2008, 48, 455–463 http://dx.doi.org/10.1177/0091270007313391[Crossref]
• [47] Cohen A.F., Land G.S., Breimer D.D., Yuen W.C., Winton C., Peck A.W., Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans, Clin. Pharmacol. Ther., 1987, 42, 535–541 http://dx.doi.org/10.1038/clpt.1987.193[Crossref]
• [48] Garnett W.R., Lamotrigine: pharmacokinetics, J. Child. Neurol. 1997, 12, 10–5 http://dx.doi.org/10.1177/0883073897012001041[Crossref]
• [49] Hussein Z., Posner J., Population pharmacokinetics of lamotrigine in patients with epilepsy: retrospective analysis of routine monitoring data, Br. J. Clin. Pharmacol., 1997, 43, 457–465 http://dx.doi.org/10.1046/j.1365-2125.1997.00594.x[Crossref]
• [50] Richens A., Pharmacokinetics of lamotrigine, In: Richens A (ed), Clinical update on lamotrigine: a novel antiepileptic agent, Kent, Wells Medical Limited, 1992, 21–27
• [51] Moris R.G., Black A.B., Harris A.L., Batty A.B., Sallustio B.C., Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service, Br. J. Clin. Pharmacol., 1998, 46, 547–551 http://dx.doi.org/10.1046/j.1365-2125.1998.00835.x[Crossref]
• [52] Zufia L., Aldaz A., Ibanez N., Viteri C., LC method for the therapeutic drug monitoring of lamotrigine: evaluation of the assay performance and validation of its application in the routine area, J. Pharm. Biomed. Anal., 2009, 49, 547–553 http://dx.doi.org/10.1016/j.jpba.2008.11.030[Crossref]
• [53] Lamictal® (Tablets), US prescribing information, Greenville, NC, GlaxoSmithKline, 2005
• [54] Brodie M.J., Yuen A.W.C., Group S., Lamotrigine substitution study: evidence for synergism with sodium valproate, Epilepsy Res., 1997, 26, 423–432 http://dx.doi.org/10.1016/S0920-1211(96)01007-8[Crossref]
• [55] Pisani F., Oteri G., Russo M.F., Di Perri R., Perucca E., Richens A., The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction, Epilepsia, 1999, 40, 1141–1146 http://dx.doi.org/10.1111/j.1528-1157.1999.tb00832.x[Crossref]
• [56] Moeller J.J., Rahey S.R., Sadler R.M., Lamotriginevalproic acid combination therapy for medically refractory epilepsy, Epilepsia, 2009, 50, 475–479 http://dx.doi.org/10.1111/j.1528-1167.2008.01866.x[Crossref]

Identifiers

DOI

10.2478/s11536-013-0158-5